Raltegravir

Category: pharmacological

Aliases: Isentress

Pharmacological Mechanism

First-in-class HIV integrase strand-transfer inhibitor (INSTI) — blocks viral DNA integration into host genome. Largely supplanted by dolutegravir + bictegravir for once-daily dosing + better resistance barrier.

Half-Life (t½)

PO: 9h

Dosing Guidelines

• PO: Typical 400mg (Range: 400 - 800 mg)

Target Organ Systems

• immune-hematologic